MedTrace Logo

Acamprosate in the Treatment of Binge-Eating Disorder

NCT00511940 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2011-06-22

No results posted yet for this study

Summary

The purpose of this research study is to determine the efficacy (how well it works), tolerability and safety of acomprosate compared with placebo in patients with binge eating disorder.

Conditions

  • Binge Eating Disorder

Interventions

DRUG

acamprosate

999 mg/day - 2997 mg/day, oral

OTHER

placebo

oral, placebo

Sponsors & Collaborators

  • Forest Laboratories

    collaborator INDUSTRY

  • University of Cincinnati

    collaborator OTHER

  • Lindner Center of HOPE

    lead OTHER

Principal Investigators

  • Susan L McElroy, MD · Lindner Center of HOPE

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-04-30
Primary Completion
2011-01-31
Completion
2011-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00511940 on ClinicalTrials.gov